HSBC WAR. CALL 12/25 TDXP/ DE000HS9LHR7 /
2024-12-23 9:36:04 PM | Chg.0.0000 | Bid9:59:44 PM | Ask9:59:44 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.5700EUR | 0.00% | 0.5700 Bid Size: 10,000 |
0.6200 Ask Size: 10,000 |
TECDAX | 4,100.00 EUR | 2025-12-19 | Call |
GlobeNewswire
07-22
MiddleGround Capital enters into Investment Agreement with STEMMER IMAGING AG and announces intentio...
GlobeNewswire
2018-06-12
Software AG acquires Technology Scale-up TrendMiner for analysis and visualization of time series da...
GlobeNewswire
2016-12-13
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...
GlobeNewswire
2016-12-06
MorphoSys Presents Updated Clinical Data for Blood Cancer Candidate MOR208 in NHL and CLL at ASH 201...
GlobeNewswire
2016-12-06
MorphoSys Presents Updated Clinical Results for Anti-CD38 Antibody MOR202 at ASH 2016
GlobeNewswire
2016-11-28
MorphoSys Announces That Its Licensee Janssen Has Submitted a Marketing Authorisation Application Fo...
GlobeNewswire
2016-11-17
MorphoSys Announces That Its Licensee Janssen Has Submitted Biologics License Application For Guselk...
GlobeNewswire
2016-11-15
MorphoSys Announces That Its Licensee Janssen Has Presented Positive Clinical Data of Guselkumab in ...
GlobeNewswire
2016-11-08
Anke Linnartz joins MorphoSys as Head of Corporate Communications and Investor Relations
GlobeNewswire
2016-11-03
MorphoSys Announces Presentations of Clinical Data at Upcoming American Society of Hematology (ASH) ...
GlobeNewswire
2016-11-02
MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatol...
GlobeNewswire
2016-10-20
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial with Novel Cancer Antibody
GlobeNewswire
2016-10-17
MorphoSys Presents Updated Clinical Results for MOR202 at Medical Conference
GlobeNewswire
2016-10-01
MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Gusel...
GlobeNewswire
2016-10-01
Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study ...
GlobeNewswire
2016-09-29
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis